Grants and Contributions:
Title:
EUREKA Project 15211 EHAV-19 - Engineering of high-affinity soluble Angiotensin Converting Enzyme 2 (ACE2) variants as a treatment for COVID-19
Agreement Number:
956312
Agreement Value:
$600,000.00
Agreement Date:
Aug 17, 2020 - Aug 31, 2021
Description:
EUREKA Project 15211 EHAV-19 - Engineering of high affinity ACE2 variants as a treatment for Covid-19 with Austrian partner Innophore GmbH.
Organization:
National Research Council Canada
Expected Results:
Eureka promotes and supports market-oriented international R&D&I project generation, and facilitates access to financing for companies involved in its projects. EUREKA’s strength lies in its well-established international network, connecting 41 full member countries from Europe and 4 associated member countries.
Location:
Richmond, British Columbia, CA V6V 2J2
Reference Number:
172-2020-2021-Q2-956312
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
818615684
Recipient Type:
For-profit organization
Recipient's Operating Name:
SLC
Recipient's Legal Name:
SignalChem Lifesciences Corporation
Federal Riding Name:
Steveston--Richmond East
Federal Riding Number:
59031
Program:
Eureka/Eurostar
Program Purpose:
Eureka promotes and supports market-oriented international R&D&I project generation, and facilitates access to financing for companies involved in its projects. EUREKA’s strength lies in its well-established international network, connecting 41 full member countries from Europe and 4 associated member countries.
Coverage:
EUREKA is a leading facilitator of innovation, providing a proven platform for international R&D&I cooperation.
NAICS Code:
541710